The FDA has cleared United Therapeutics to begin SUMMIT, a 16-week randomized, double-blind phase 2 trial of inhaled treprostinil delivered by soft mist inhaler in roughly 40 patients with pulmonary hypertension associated with COPD. Primary endpoints address safety and tolerability, with exercise capacity and NT-proBNP as secondary measures, and an open-label extension for longer-term follow-up. The target population — an estimated 400,000 to 800,000 people in the United States — is largely undiagnosed, making detection as much a barrier as treatment.
Key Points
- Phase 2 SUMMIT trial tests inhaled treprostinil in PH-COPD patients
- Endpoints include exercise capacity and NT-proBNP over 16 weeks
- Up to 800,000 Americans affected; most remain undiagnosed
Longevity Analysis
Pulmonary hypertension in COPD sits at the intersection of gas exchange and right-heart load, where declining exercise capacity is often attributed to deconditioning or age rather than to a measurable pressure burden on the pulmonary circulation. NT-proBNP as a secondary endpoint reflects that the signal is cardiac even when the symptom presents as breathlessness — a reminder that accurate attribution determines whether a treatable mechanism is addressed or ignored. With a diagnosis gap of this scale, earlier identification through functional testing and biomarkers may matter more to outcomes than any single pharmacologic advance.
Original published by LT Wire.